Personalized Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase 3 Trial - 헬스조선

Health By The Chosun Ilbo • November 14, 2026, 4:50 AM UTC
⏱ 1 min read 👁 5 views
Direct Source Verification: This story is aggregated from The Chosun Ilbo (chosun.com). Full reporting rights and copyright belong to the primary publisher.
Read on The Chosun Ilbo ↗
Personalized Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase 3 Trial - 헬스조선
Personalized Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase 3 Trial  헬스조선
Personalized Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase 3 Trial  헬스조선
Original Source
https://health.chosun.com/english/site/data/html_dir/2026/11/14/2026111400777.html
Visit The Chosun Ilbo ↗
SHARE STORY:
𝕏 f in

Related Coverage in Health